NCT03375242 2025-06-25
Safety and Efficacy of Xalkori ROS1
Pfizer
Recruiting
Clinical Trials
8 trialsNCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT02679170 2024-08-09
Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
Pfizer
Completed
NCT03646994 2023-12-27
Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
Unknown
NCT03647111 2023-12-27
Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
Unknown
NCT04647110 2023-04-06
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
Pfizer
Completed
NCT04115410 2020-05-28
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Unknown
NCT01597258 2019-09-13
Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)
Pfizer
Completed